AQST Q1 2024 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$12M+8.3% YoY

Gross Profit

$8M63.6% margin

Operating Income

-$9M-74.3% margin

Net Income

-$13M-106.4% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-8.7%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$130M

Total Liabilities

$166M

Stockholders' Equity

-$36M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$11M	+8.3%
Gross Profit	$8M	$6M	+19.8%
Operating Income	-$9M	-$5M	-94.5%
Net Income	-$13M	$8M	-259.0%

Revenue Segments

Manufacture and Supply Revenue

$11M87%

License and Royalty Revenue

$1M9%

Co-Development and Research Fees

$403,0003%

Geographic Segments

UNITED STATES

$10M87%

Non-US

$2M13%